[go: up one dir, main page]

AR228256A1 - Procedimiento para la elaboracion de nuevos compuestos de 2-(pirimidinilamino)-1,3-diaza-2-cicloalqueno - Google Patents

Procedimiento para la elaboracion de nuevos compuestos de 2-(pirimidinilamino)-1,3-diaza-2-cicloalqueno

Info

Publication number
AR228256A1
AR228256A1 AR281109A AR28110980A AR228256A1 AR 228256 A1 AR228256 A1 AR 228256A1 AR 281109 A AR281109 A AR 281109A AR 28110980 A AR28110980 A AR 28110980A AR 228256 A1 AR228256 A1 AR 228256A1
Authority
AR
Argentina
Prior art keywords
pirimidinilamino
cicloalqueno
diaza
elaboration
procedure
Prior art date
Application number
AR281109A
Other languages
English (en)
Spanish (es)
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of AR228256A1 publication Critical patent/AR228256A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AR281109A 1979-05-18 1980-05-19 Procedimiento para la elaboracion de nuevos compuestos de 2-(pirimidinilamino)-1,3-diaza-2-cicloalqueno AR228256A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (1)

Publication Number Publication Date
AR228256A1 true AR228256A1 (es) 1983-02-15

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
AR281109A AR228256A1 (es) 1979-05-18 1980-05-19 Procedimiento para la elaboracion de nuevos compuestos de 2-(pirimidinilamino)-1,3-diaza-2-cicloalqueno

Country Status (21)

Country Link
EP (1) EP0019811A1 (sv)
JP (1) JPS55154971A (sv)
KR (1) KR830002757A (sv)
AR (1) AR228256A1 (sv)
AU (1) AU5848480A (sv)
DD (1) DD150609A5 (sv)
DK (1) DK214480A (sv)
ES (1) ES491514A0 (sv)
FI (1) FI801600A7 (sv)
GB (1) GB2052487B (sv)
GR (1) GR68453B (sv)
IE (1) IE49803B1 (sv)
IL (1) IL60086A (sv)
MA (1) MA18829A1 (sv)
NO (1) NO801469L (sv)
NZ (1) NZ193730A (sv)
OA (1) OA06533A (sv)
PL (1) PL224313A1 (sv)
PT (1) PT71251A (sv)
ZA (1) ZA802909B (sv)
ZW (1) ZW11880A1 (sv)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (de) * 1988-08-31 1990-03-01 Bayer Ag Verfahren zur herstellung von substituierten n-azinyl-n'-sulfonyl-isothioharnstoffen und n-azinyl-iminodithiokohlensaeure-s,s-diester als zwischenprodukte zu ihrer herstellung
AU9302298A (en) * 1997-09-03 1999-03-22 Eli Lilly And Company Pyrimidine derivatives
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022607A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03005609A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
HRP20030608A2 (en) * 2001-01-31 2005-06-30 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment
DK1483247T3 (da) 2002-03-13 2009-08-17 Euro Celtique Sa Arylsubstituerede pyrimidiner og anvendelsen deraf
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
CN1642422A (zh) * 2002-03-15 2005-07-20 西巴特殊化学品控股有限公司 4-氨基嘧啶及其在表面抗菌处理中的应用
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk-3的抑制剂的吡唑组合物
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7737151B2 (en) 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
CA2627808A1 (en) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2008057940A1 (en) 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
MX2009006690A (es) 2006-12-19 2009-07-31 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.
ES2435997T3 (es) 2007-03-09 2013-12-26 Vertex Pharmaceuticals, Inc. Aminopirimidinas útiles como inhibidores de las proteínas cinasas
JP2010520887A (ja) 2007-03-09 2010-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリジン
JP5393489B2 (ja) 2007-03-09 2014-01-22 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
EP2146982A2 (en) 2007-04-13 2010-01-27 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CA2685876A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
WO2008137621A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AR067762A1 (es) 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
JP2012501971A (ja) 2008-09-03 2012-01-26 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶および共結晶を含む薬学的処方物
TW201639852A (zh) * 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
US20240002369A1 (en) * 2020-11-12 2024-01-04 3Z Ehf Novel treatments of attention deficit/hyperactivity disorder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) * 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines

Also Published As

Publication number Publication date
OA06533A (fr) 1981-07-31
GB2052487A (en) 1981-01-28
GB2052487B (en) 1983-05-11
ES8104279A1 (es) 1981-04-16
IE49803B1 (en) 1985-12-25
PL224313A1 (sv) 1981-02-13
ZW11880A1 (en) 1980-12-17
ZA802909B (en) 1981-05-27
ES491514A0 (es) 1981-04-16
NZ193730A (en) 1982-12-21
NO801469L (no) 1980-11-19
KR830002757A (ko) 1983-05-30
FI801600A7 (sv) 1981-01-01
IE801023L (en) 1980-11-18
IL60086A (en) 1984-03-30
AU5848480A (en) 1980-11-20
DD150609A5 (de) 1981-09-09
PT71251A (en) 1980-06-01
IL60086A0 (en) 1980-07-31
DK214480A (da) 1980-11-19
EP0019811A1 (de) 1980-12-10
JPS55154971A (en) 1980-12-02
GR68453B (sv) 1981-12-30
MA18829A1 (fr) 1980-12-31

Similar Documents

Publication Publication Date Title
AR228256A1 (es) Procedimiento para la elaboracion de nuevos compuestos de 2-(pirimidinilamino)-1,3-diaza-2-cicloalqueno
ES514585A0 (es) Procedimiento para la obtencion de derivados de oxazol trisustituidos.
AR224008A1 (es) Procedimiento para preparar polihidro-3,7-dimetil-8-(2-(tetrahidro-4-hidroxi-6-oxo-2h-piran-2-il)-etil)-1-naftil-2-metilbutirato
ES535946A0 (es) Procedimiento para preparar 2-(2-benzoil sustituido)-1, 3-ciclohexanodionas
ES488196A0 (es) Procedimiento para la preparacion de compuestos de dioxacinabasicos
AR230437A1 (es) Procedimiento para la fabricacion de derivados de 2-(dialquamino,pirrolidinil o piperidinil)-alquil-tio-quinolina
AR227527A1 (es) Procedimiento para la elaboracion de nuevos compuestos n-oxaciclilalquil-piperidil-diazoicos
ES497366A0 (es) Un procedimiento para la preparacion de nuevos compuestos de mercaptoorganosiloxano.
ES493846A0 (es) Un procedimiento para la preparacion de nuevos compuestos oligolipidos.
ES491341A0 (es) Procedimiento para la obtencion de derivados fluorados de triazolil-butano, de efecto fungicida
AR227286A1 (es) Procedimiento para la elaboracion de nuevos compuestos de 1-(2-imidazolidin-1-ilo-alquil)-3-fenilurea o tiourea
ES489689A0 (es) Procedimiento para preparar compuestos de isotiourea
MX6580E (es) Procedimiento para la preparacion de compuestos acetoximetil-penam
ES493499A0 (es) Procedimiento para preparar compuestos de 3-metilemazetidina
AR213659A1 (es) Procedimiento para la preparacion de 2-(4-(aroil o heteroaroil)-piperazin-1-il)-4-amino-6,7-dimetoxiquinazolinas
AR224318A1 (es) Procedimiento para la preparacion de compuestos de piran-4-ona
ES488709A0 (es) Procedimiento para la preparacion de compuestos diorganomag-nesicos,r2mg
AR223319A1 (es) Procedimiento para la elaboracion de compuestos de 6-amino-penam
ES493016A0 (es) Procedimiento para la preparacion de nuevas 2-(perhi- dro-1,4-diazino)-pirimido(5,4-d)pirimidinas
ES494211A0 (es) Procedimiento para la preparacion de nuevos derivados de 10-halogen-e-homo-eburnanos.
AR228330A1 (es) Procedimiento para la preparacion de nuevas 4-(3-trifluormetilfenil)-1,2,3,6-tetrahidropiridinas
AR216675A1 (es) Procedimiento para la preparacion de 2-(gamma-(1-piperidinil)propil)-1,2-benzisotiazol-3-ona
ES496509A0 (es) Procedimiento para la preparacion de nuevos compuestos ca- tionicos
MX5101E (es) Procedimiento para la preparacion de 2-(2',2',2',-trihalogenoetil)-4-halogenociclobutan-1-onas
ES492672A0 (es) Procedimiento para la preparacion de compuestos de nitroari-lo substituidos